NasdaqCM - Nasdaq Real Time Price • USD
Moleculin Biotech, Inc. (MBRX)
As of 11:09 AM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 2 | 2 |
| Avg. Estimate | -3.53 | -3.22 | -11.54 | -7.42 |
| Low Estimate | -3.59 | -3.62 | -12.03 | -8.35 |
| High Estimate | -3.47 | -2.82 | -11.05 | -6.49 |
| Year Ago EPS | -4.2 | -3 | -15.07 | -11.54 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 2 | 2 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -3.75 | -4.1 | -3.55 | -3.05 |
| EPS Actual | -4.2 | -3 | -2.85 | -5.02 |
| Difference | -0.45 | 1.1 | 0.7 | -1.97 |
| Surprise % | -12.00% | 26.80% | 19.70% | -64.60% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -3.53 | -3.22 | -11.54 | -7.42 |
| 7 Days Ago | -3.53 | -3.22 | -11.54 | -7.42 |
| 30 Days Ago | -0.16 | -0.16 | -0.78 | -0.77 |
| 60 Days Ago | -0.16 | -0.16 | -0.78 | -0.77 |
| 90 Days Ago | -0.19 | -0.16 | -0.8 | -0.78 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | 1 | 2 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | MBRX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 16.00% | -- | -- | 0.80% |
| Next Qtr. | -7.30% | -- | -- | 9.60% |
| Current Year | 23.40% | -- | -- | 4.50% |
| Next Year | 35.70% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Maintains | Roth MKM: Buy to Buy | 4/12/2024 |
| Maintains | Maxim Group: Buy to Buy | 3/26/2024 |
| Initiated | HC Wainwright & Co.: Buy | 12/14/2023 |
| Maintains | Roth MKM: Buy | 4/18/2023 |
| Reiterates | Oppenheimer: Outperform | 3/24/2023 |
Related Tickers
GLMD Galmed Pharmaceuticals Ltd.
0.3775
+0.08%
VRPX Virpax Pharmaceuticals, Inc.
3.6800
-5.88%
CNSP CNS Pharmaceuticals, Inc.
0.2081
+1.51%
PRTG Portage Biotech Inc.
0.2583
+5.86%
RNAC Cartesian Therapeutics, Inc.
17.64
+2.08%
TRVN Trevena, Inc.
0.3560
-2.75%
ALRN Aileron Therapeutics, Inc.
4.8600
-2.80%
GNPX Genprex, Inc.
2.3300
+5.43%
ZVSA ZyVersa Therapeutics, Inc.
0.6207
-1.00%
APVO Aptevo Therapeutics Inc.
0.7361
-4.40%